• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $IMRA

    IMARA Inc.

    Subscribe to $IMRA
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. It develops IMR-687, an oral, once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: imaratx.com

    Peers

    $ACIU

    Recent Analyst Ratings for IMARA Inc.

    DatePrice TargetRatingAnalyst
    1/6/2022$12.00 → $4.00Equal-Weight
    Morgan Stanley
    11/30/2021$10.00Buy
    HC Wainwright & Co.
    8/11/2021$33.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    See more ratings

    IMARA Inc. SEC Filings

    View All

    SEC Form 144 filed by IMARA Inc.

    144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/15/24 5:04:57 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by IMARA Inc.

    144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

    12/20/23 6:06:54 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by IMARA Inc.

    144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

    12/19/23 5:27:50 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by IMARA Inc.

    10-Q - Enliven Therapeutics, Inc. (0001672619) (Filer)

    11/9/23 4:15:39 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IMARA Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)

    11/9/23 4:10:11 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by IMARA Inc.

    10-Q - Enliven Therapeutics, Inc. (0001672619) (Filer)

    8/10/23 4:16:58 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IMARA Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)

    8/10/23 4:10:30 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by IMARA Inc.

    424B5 - Enliven Therapeutics, Inc. (0001672619) (Filer)

    7/6/23 4:06:14 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by IMARA Inc.

    EFFECT - Enliven Therapeutics, Inc. (0001672619) (Filer)

    7/5/23 12:15:24 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by IMARA Inc.

    S-3 - Enliven Therapeutics, Inc. (0001672619) (Filer)

    6/23/23 5:28:15 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IMARA Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley reiterated coverage on Imara with a new price target

    Morgan Stanley reiterated coverage of Imara with a rating of Equal-Weight and set a new price target of $4.00 from $12.00 previously

    1/6/22 10:34:33 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. initiated coverage on Imara with a new price target

    HC Wainwright & Co. initiated coverage of Imara with a rating of Buy and set a new price target of $10.00

    11/30/21 7:23:31 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Imara downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Imara from Overweight to Equal-Weight and set a new price target of $12.00 from $33.00 previously

    8/11/21 6:17:27 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Citigroup resumed coverage on IMARA with a new price target

    Citigroup resumed coverage of IMARA with a rating of Buy and set a new price target of $30.00

    5/12/21 7:57:15 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley reiterated coverage on Imara with a new price target

    Morgan Stanley reiterated coverage of Imara with a rating of Overweight and set a new price target of $33.00 from $34.00 previously

    4/19/21 10:38:06 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVB Leerink reiterated coverage on IMARA with a new price target

    SVB Leerink reiterated coverage of IMARA with a rating of Outperform and set a new price target of $42.00 from $59.00 previously

    3/15/21 8:10:26 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley reiterated coverage on IMARA with a new price target

    Morgan Stanley reiterated coverage of IMARA with a rating of Overweight and set a new price target of $34.00 from $35.00 previously

    3/15/21 8:09:46 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley reiterated coverage on Imara with a new price target

    Morgan Stanley reiterated coverage of Imara with a rating of Overweight and set a new price target of $34.00 from $35.00 previously

    3/8/21 10:53:38 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVB Leerink reiterated coverage on Imara with a new price target

    SVB Leerink reiterated coverage of Imara with a rating of Outperform and set a new price target of $42.00 from $59.00 previously

    3/8/21 5:13:33 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IMARA Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    5am Partners Vi, Llc sold $12,292,500 worth of shares (825,000 units at $14.90) (SEC Form 4)

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/16/24 4:15:31 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Phillips Andrew John

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/15/24 9:04:08 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Patel Anish

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/15/24 9:02:21 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Lyssikatos Joseph P

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/15/24 9:00:28 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Kintz Samuel

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/15/24 8:56:11 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Hohl Benjamin

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/15/24 8:54:11 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Heyman Richard A.

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/15/24 8:52:32 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Gupta Rishi

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/15/24 8:50:25 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Derynck Mika K

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/15/24 8:48:40 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Collins Helen Louise

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/15/24 8:46:29 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IMARA Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bitwise Announces Updates to ETF Lineup

    SAN FRANCISCO, June 30, 2026 /PRNewswire/ -- Bitwise Asset Management, the global crypto asset manager with $11 billion in client assets (As of April 1, 2026), plans to close and liquidate the Bitwise COIN Option Income Strategy ETF (ICOI), Bitwise MARA Option Income Strategy ETF (IMRA), Bitwise MSTR Option Income Strategy ETF (IMST), Bitwise GME Option Income Strategy ETF (IGME), Bitwise CRCL Option Income Strategy ETF (ICRC), and Bitwise Ethereum Option Income Strategy ETF (IETH). TickerETF NameListing ExchangeLast Day toPurchaseCreationUnitsLast Day ofTradingFinal NAVCalculationDateLiquidation DateICOIBitwise COINOption Inco

    6/30/26 4:01:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, June 25, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistributionRate30-Day SECYieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturn*Bitwise COINOption Income Strategy ETFICOI$0.1676820.00 %0.00 %100.00 %6/26/20266/30/2026-11.80 %-51.38 %-29.37 %Bitwise MARAOption Income Strategy ETFIMRA$0.119568.44 %0.00 %100.00 %6/26/20266/30/2026-3.92 %-34.66 %-19.84 %Bitwise MSTROption

    6/25/26 4:49:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, May 21, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturn*Bitwise COINOption Income Strategy ETFICOI$0.2566025.37 %0.00 %100.00 %5/22/20265/27/20262.41 %-35.98 %-20.61 %Bitwise MARAOption Income Strategy ETFIMRA$0.1710111.93 %0.00 %100.00 %5/22/2026

    5/21/26 4:01:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturn*Bitwise COINOption Income Strategy ETFICOI$0.2544725.40 %0.00 %100.00 %4/24/20264/28/2026-4.73 %-28.24 %-24.19 %Bitwise MARAOption Income Strategy ETFIMRA$0.1476311.25 %0.00 %100.00 %4/24/2

    4/23/26 5:06:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, March 26, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturnBitwise COINOption Income Strategy ETFICOI$0.5161850.68 %0.00 %100.00 %03/27/202603/31/30264.28 %N/A-27.64 %Bitwise MARAOption Income Strategy ETFIMRA$0.2499422.66 %0.00 %100.00 %03/27/20260

    3/26/26 4:08:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturnBitwise COINOption Income Strategy ETFICOI$0.6149255.74 %0.00 %100.00 %02/27/202603/03/2026-12.65 %N/A-25.29 %Bitwise MARAOption Income Strategy ETFIMRA$0.3058725.67 %0.00 %100.00 %02/27/2026

    2/26/26 4:22:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Jan. 22, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH.  Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $0.50284 36.87 % 0.00 % 50.00 % 01/23/2026 01/27/2026 -4.93 % N/A -10.58 % Bitwise MARA Option Income Strategy ETF IMRA $0.20782 14

    1/22/26 4:21:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Dec. 24, 2025 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $2.24702 140.11 % 0.00 % 100.00 % 12/26/2025 12/30/2025 -2.82 % N/A -7.33 % Bitwise MARA Option Income Strategy ETF IMRA $1.41664 100.18 % 0.00 % 100.00 % 12/26/2025 12/30/2025 -9.45 % N/A -35.18 % Bitwise MSTR Option Income Strategy ETF IMST $1.30

    12/24/25 1:12:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Nov. 26, 2025 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date PaymentDate 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $2.59493 140.33 % 0.00 % 100.00 % 11/28/2025 12/2/2025 -27.20 % N/A -5.10 % Bitwise MARA Option Income Strategy ETF IMRA $1.69441 100.07 % 0.00 % 100.00 % 11/28/2025 12/2/2025 -40.17 % N/A -28.64 % Bitwise MSTR Option Income Strategy ETF IMST $1.503

    11/26/25 4:30:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, and IGME

    Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, and IGME. Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since Inception Return Bitwise MSTR Option Income Strategy ETF IMST $2.88888 120.08% 0.00% 100% 10/24/2025 10/28/2025 -16.11% N/A -11.74% Bitwise COIN Option Income Strategy ETF ICOI $3.93547 150.20% 0.00

    10/23/25 4:16:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IMARA Inc. Leadership Updates

    Live Leadership Updates

    View All

    Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

    Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D., FACC, FASE Imara's new Vice President of Clinical Development BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, announced data today in three preclinical mouse models of heart failure with preserved ejection fraction (HFpEF) treated with tovinontrine (IMR-687). Sele

    11/8/21 7:00:00 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors

    BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the election of Laura A. Williams, M.D., MPH to its Board of Directors. Dr. Williams brings 25 years of early-to-late-stage drug development experience across multiple therapeutic areas, as well as expertise in patient advocacy to Imara. "We're thrilled to welcome Dr. Williams to our Board," said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. "In addition to her significant experience leading clinical

    6/30/21 7:00:00 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer

    BOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the appointment of Kenneth Attie, M.D. as Senior Vice President and Chief Medical Officer. Dr. Attie joins Imara with over 30 years of experience within academia and the biopharmaceutical industry, most recently at Acceleron Pharma, Inc. where he led global clinical development efforts that led to the recent FDA and EMA approvals of a new treatment for patients with rare anemias, including beta-thalassemia.  “We are exc

    1/20/21 7:00:00 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IMARA Inc. Financials

    Live finance-specific insights

    View All

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, June 25, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistributionRate30-Day SECYieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturn*Bitwise COINOption Income Strategy ETFICOI$0.1676820.00 %0.00 %100.00 %6/26/20266/30/2026-11.80 %-51.38 %-29.37 %Bitwise MARAOption Income Strategy ETFIMRA$0.119568.44 %0.00 %100.00 %6/26/20266/30/2026-3.92 %-34.66 %-19.84 %Bitwise MSTROption

    6/25/26 4:49:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, May 21, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturn*Bitwise COINOption Income Strategy ETFICOI$0.2566025.37 %0.00 %100.00 %5/22/20265/27/20262.41 %-35.98 %-20.61 %Bitwise MARAOption Income Strategy ETFIMRA$0.1710111.93 %0.00 %100.00 %5/22/2026

    5/21/26 4:01:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturn*Bitwise COINOption Income Strategy ETFICOI$0.2544725.40 %0.00 %100.00 %4/24/20264/28/2026-4.73 %-28.24 %-24.19 %Bitwise MARAOption Income Strategy ETFIMRA$0.1476311.25 %0.00 %100.00 %4/24/2

    4/23/26 5:06:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, March 26, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturnBitwise COINOption Income Strategy ETFICOI$0.5161850.68 %0.00 %100.00 %03/27/202603/31/30264.28 %N/A-27.64 %Bitwise MARAOption Income Strategy ETFIMRA$0.2499422.66 %0.00 %100.00 %03/27/20260

    3/26/26 4:08:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Feb. 26, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturnBitwise COINOption Income Strategy ETFICOI$0.6149255.74 %0.00 %100.00 %02/27/202603/03/2026-12.65 %N/A-25.29 %Bitwise MARAOption Income Strategy ETFIMRA$0.3058725.67 %0.00 %100.00 %02/27/2026

    2/26/26 4:22:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Jan. 22, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH.  Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $0.50284 36.87 % 0.00 % 50.00 % 01/23/2026 01/27/2026 -4.93 % N/A -10.58 % Bitwise MARA Option Income Strategy ETF IMRA $0.20782 14

    1/22/26 4:21:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Dec. 24, 2025 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $2.24702 140.11 % 0.00 % 100.00 % 12/26/2025 12/30/2025 -2.82 % N/A -7.33 % Bitwise MARA Option Income Strategy ETF IMRA $1.41664 100.18 % 0.00 % 100.00 % 12/26/2025 12/30/2025 -9.45 % N/A -35.18 % Bitwise MSTR Option Income Strategy ETF IMST $1.30

    12/24/25 1:12:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, Nov. 26, 2025 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date PaymentDate 1-Month Return 1-Year Return Since InceptionReturn Bitwise COIN Option Income Strategy ETF ICOI $2.59493 140.33 % 0.00 % 100.00 % 11/28/2025 12/2/2025 -27.20 % N/A -5.10 % Bitwise MARA Option Income Strategy ETF IMRA $1.69441 100.07 % 0.00 % 100.00 % 11/28/2025 12/2/2025 -40.17 % N/A -28.64 % Bitwise MSTR Option Income Strategy ETF IMST $1.503

    11/26/25 4:30:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, and IGME

    Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, and IGME. Fund Ticker Distribution Per Share Distribution Rate 30-Day SEC Yield Return of Capital Ex-Date / Record Date Payment Date 1-Month Return 1-Year Return Since Inception Return Bitwise MSTR Option Income Strategy ETF IMST $2.88888 120.08% 0.00% 100% 10/24/2025 10/28/2025 -16.11% N/A -11.74% Bitwise COIN Option Income Strategy ETF ICOI $3.93547 150.20% 0.00

    10/23/25 4:16:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Enliven Therapeutics and Imara Announce Merger Agreement

    Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven's portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors including Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences and Commodore Capital and support from all existing Enliven investorsCompanies to host co

    10/13/22 4:35:22 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    IMARA Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by IMARA Inc. (Amendment)

    SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/16/24 4:15:28 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

    SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/14/24 8:53:21 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

    SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/14/24 4:58:16 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

    SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/14/24 4:05:33 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

    SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/14/24 3:45:10 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

    SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/14/24 3:31:31 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

    SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/9/24 9:03:06 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

    SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/7/24 12:16:23 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by IMARA Inc. (Amendment)

    SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/2/24 4:15:44 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13D/A filed by IMARA Inc. (Amendment)

    SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    8/28/23 4:15:25 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care